Predictive factors for the outcome of high flow nasal cannula therapy in a pediatric intensive care unit: Is the SpO<sub>2</sub>/FiO<sub>2</sub> ratio useful?


Can F. K., Anil A. B., Anil M., Zengin N., Durak F., Alparslan C., ...Daha Fazla

JOURNAL OF CRITICAL CARE, cilt.44, ss.436-444, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.jcrc.2017.09.003
  • Dergi Adı: JOURNAL OF CRITICAL CARE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.436-444
  • Manisa Celal Bayar Üniversitesi Adresli: Hayır

Özet

Objectives: To determine the predictive factors for the outcome of high-flow nasal cannula (HFNC) therapy in a pediatric intensive care unit (PICU). Materials and methods: We prospectively included all patients with acute respiratory distress/failure aged 1 month to 18 years who were admitted to the PICU between January 2015 and May 2016 and treated with HFNC as a primary support and for postextubation according to our pre-established protocol. HFNC failure was defined as the need for escalation to non-invasive ventilation (NIV) or invasive mechanical ventilation (MV). HFNC responders and nonresponders were compared based on clinical data obtained just before HFNC and at 30, 60, and 120 min, 12, 24, and 48 h, and at the end of therapy. Results: A total of 204 patients (median age: 16.5 months) participated in the study. Twenty-six (12.7%) patients required escalation (4 to NIV and 22 to MV). Age > 120 months, higher PRISM-III and respiratory scores, and a lower SpO(2)/FiO(2) (S/F) ratio at admission were predictors of HFNC failure. Achievement of the S/F > 200 goal at 60 min significantly predicted successful HFNC. Conclusion: Monitoring the S/F ratio might be useful and practical to avoid delaying escalation to another ventilation support. Failure to achieve S/F > 200 at 60 min should be a warning for the escalation of respiratory support. (C) 2017 Elsevier Inc. All rights reserved.